Oncology development
What longer follow-up revealed in the HARMONi trial
Review Insmed’s 12-month open-label TPIP findings in pulmonary arterial hypertension and what sites need for the PALM-PAH Phase 3 trial.
By Lampgen Clinical Research
1 min read · estimated
What the source reported
Summit’s July 2026 update to the Phase 3 HARMONi trial reported an overall survival hazard ratio of 0.76 in both the full trial population and the Western subgroup. The trial compared investigational ivonescimab plus chemotherapy with placebo plus chemotherapy in previously treated EGFR-mutated nonsquamous non-small cell lung cancer. The primary overall survival analysis had missed statistical significance.
What this means for trial teams
Western follow-up was shorter at the primary analysis. The later data help interpret the apparent regional difference. For clinical teams, the practical implication is to plan survival follow-up beyond treatment discontinuation, reconcile vital status before database cuts, and monitor follow-up completeness by region.